Candida kefyr: An Emerging Fungal Pathogen

Candida kefyr, now formally reclassified as Kluyveromyces marxianus, is a yeast species that has shifted from a footnote in microbiology textbooks to a genuine clinical concern over the past two decades. Once considered a harmless organism found in fermented dairy products, it is increasingly showing up in bloodstream infections and other invasive fungal diseases, particularly among people with weakened immune systems.¹ What makes C. kefyr especially interesting is the tension in its identity: the same organism prized by food scientists for fermenting milk and producing aromatic compounds can, in the right host, cause life-threatening infections that resist common antifungal drugs.

From Dairy Culture to Hospital Wards

C. kefyr gets its name from kefir, the fermented milk drink where it was first identified. It naturally inhabits dairy environments and plays an active role in traditional fermented foods across many cultures. In Zimbabwean naturally fermented cow’s milk (amasi), for example, C. kefyr grows alongside lactic acid bacteria and contributes to the fermentation process.² It turns up in cheese, yogurt, kefir grains, and raw milk from various animal species. Studies have even isolated it from goat milk, where it showed protease and hemolysin activity, hinting that even food-associated strains carry some virulence traits.³

This dairy connection matters clinically because it means healthy people can carry C. kefyr in their gut as part of the normal mycobiome. Colonization itself is not disease. The trouble begins when immune defenses break down, allowing the yeast to cross into the bloodstream or invade tissues. That transition from harmless colonizer to invasive pathogen is the core of C. kefyr’s emerging story.

Who Gets Sick

The patients most affected by invasive C. kefyr infections share a common thread: severely compromised immune systems. The strongest association is with blood cancers. A study at a major cancer center found that both colonization and bloodstream infection caused by C. kefyr increased over the study period, and by 2010, C. kefyr accounted for roughly one in six candidemia episodes among patients with hematologic malignancies.⁴ That is a striking proportion for a species most clinicians would not have thought to worry about a decade earlier.

Neutropenia, the dangerously low white blood cell count that results from chemotherapy, is a key risk factor. The combination of a weakened immune barrier and prior antifungal exposure creates conditions where C. kefyr can fill a niche that other Candida species have been suppressed out of. Early reports flagged it as an emerging cause of hospital-acquired bloodstream infections specifically in neutropenic leukemia patients.⁵ A broader look at candidemia in patients with underlying cancers confirmed that those with hematologic diseases were more often infected by less common Candida species, including C. kefyr, compared to patients with solid tumors.⁶

Organ transplant recipients represent another growing at-risk group. The immunosuppressive drugs these patients take to prevent organ rejection also dampen the very immune responses needed to keep opportunistic fungi in check. C. kefyr has been reported as an emerging cause of invasive fungal infection in this population, adding to the challenge transplant teams already face managing infections.¹

How Common Is It, Really

C. kefyr remains a relatively rare cause of candidemia compared to the dominant species like C. albicans, C. glabrata, and C. parapsilosis. In a study across two teaching hospitals in Egypt, only a single C. kefyr isolate was detected among adult candidemia cases, and one among pediatric patients, representing about one percent of all Candida bloodstream isolates.⁷ Those numbers might sound trivially small, and in absolute terms they are. But the trend matters more than any single snapshot. The Egyptian study was itself noteworthy as the first report of C. kefyr candidemia from that region, meaning it had simply not been detected there before.

The cancer-center data paints a clearer picture of rising incidence. The year-over-year increase in both colonization and bloodstream infection by C. kefyr was statistically significant, with a marked acceleration after 2009.⁴ Whether this reflects genuine biological emergence, improved diagnostic methods picking up cases that were previously missed, or shifts in antifungal prescribing patterns that create ecological space for C. kefyr is an open question. All three factors probably contribute.

What Makes C. Kefyr Pathogenic

Compared to C. albicans, the best-studied Candida species, C. kefyr seems to carry a lighter arsenal of virulence tools. But “lighter” does not mean “absent,” and the picture has become more complicated as researchers have looked more closely.

Protease production is the most consistently reported virulence trait. Proteases are enzymes that break down proteins in host tissues, helping the yeast invade and persist. A comparative study of clinical and environmental C. kefyr isolates found protease activity in about 94% of strains tested.⁸ That is a high rate, comparable to C. albicans. Phospholipase activity, another tissue-damaging enzyme, is a different story. The same study found it in only about 3% of C. kefyr isolates, and earlier work noted only a few C. kefyr strains produced both phospholipase and protease, in contrast to C. albicans where the vast majority produce both.⁹

Biofilm formation, the ability to build a sticky protective community on surfaces like catheters and medical devices, has yielded mixed results. One study using urinary catheter material found that C. kefyr did not form biofilms at all, while other species like C. krusei did.¹⁰ Yet other lab work showed that C. kefyr could produce mature biofilms on both polystyrene surfaces and sections of central venous catheters.¹¹ A larger study reported biofilm formation in about 82% of C. kefyr isolates.⁸ The contradiction probably reflects differences in experimental conditions, strain origin, and the surfaces tested. The practical takeaway is that clinicians should not assume C. kefyr is incapable of forming biofilms on medical devices.

An intriguing observation from veterinary medicine adds another dimension. When C. kefyr colonized the uteri of cows, microscopy showed yeast cells being actively engulfed by macrophages, with only mild inflammation present.¹² This suggests that in an immunocompetent host, the innate immune system handles C. kefyr efficiently. The yeast becomes dangerous when that phagocytic response is impaired, which aligns with the clinical pattern of infections clustering in severely immunosuppressed patients.

Antifungal Susceptibility and Emerging Resistance

One of the reasons C. kefyr initially drew less clinical alarm than species like C. krusei or C. glabrata is that it was considered broadly susceptible to standard antifungal drugs. That reputation is no longer entirely reliable.

Amphotericin B, a workhorse antifungal, generally performs well against C. kefyr. A study examining isolates from clinical samples and dairy products found that about 79% of isolates were wild-type to amphotericin B, with the lowest minimum inhibitory concentrations compared to other antifungals tested.¹³ However, that same study flagged concerning patterns with fluconazole: healthy carriers, patients, and dairy products all yielded isolates with elevated fluconazole minimum inhibitory concentrations, with healthy individuals actually showing the highest values. This is a red flag because it means resistant strains circulate even outside the hospital setting.

Voriconazole susceptibility was also variable, with only about 31% of isolates classified as wild-type in that study.¹³ This is a worrying finding because voriconazole is a go-to drug for many invasive fungal infections, and if a large proportion of C. kefyr isolates are not susceptible, empiric therapy might fail before the lab results come back.

At the molecular level, researchers have begun to uncover the genetic basis of resistance. In one azole-resistant C. kefyr strain recovered from a stem cell transplant patient, two mutations in the ERG11 gene were identified. One of these, K151E, corresponds to a well-known resistance mutation in C. albicans. The combination of both mutations was thought to explain the strain’s high-level resistance to both fluconazole and voriconazole.¹⁴ A separate investigation in Kuwait found that some fluconazole-resistant isolates carried only synonymous mutations in ERG11, meaning no amino acid change, which implies other resistance mechanisms like drug efflux pumps may also be at work.¹⁵ The resistance picture is clearly more complex than a single gene story.

How C. Kefyr Gets Identified in the Lab

Accurate identification matters because treatment decisions depend on knowing which Candida species you are dealing with. C. kefyr can be tricky. On standard chromogenic agar media used to differentiate Candida species by colony color, C. kefyr colonies appear pink, which is the same color as C. tropicalis, a much more common pathogen. One study evaluating a newer chromogenic agar found 100% sensitivity and specificity for detecting the combined C. tropicalis/C. kefyr group, but the agar could not distinguish between the two species within that group.¹⁶ For a lab relying solely on chromogenic media, a C. kefyr infection could easily be reported as C. tropicalis, leading to incorrect treatment assumptions.

Molecular methods, including sequencing of ribosomal DNA regions, are more reliable for definitive identification. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS), now standard in many hospital labs, can also distinguish C. kefyr from look-alikes. But in resource-limited settings where these tools are unavailable, misidentification remains a genuine concern. This diagnostic gap may partly explain why C. kefyr has been underreported historically: cases were happening but were being attributed to other species.

Treating C. Kefyr Infections

There is no single standardized treatment protocol for invasive C. kefyr disease, partly because the species is uncommon enough that no large clinical trials have been conducted. Clinicians typically rely on antifungal susceptibility testing and extrapolate from broader Candida treatment guidelines.

Animal model data provides some direction. In a mouse model of systemic candidiasis caused by C. kefyr, caspofungin (an echinocandin) showed the highest efficacy in reducing fungal burden in the kidneys and lowering blood markers of infection, outperforming both amphotericin B and fluconazole.¹⁷ Amphotericin B and caspofungin both killed the yeast outright in lab tests, while fluconazole merely stopped it from growing without killing it. This distinction between fungicidal and fungistatic activity matters in severely immunocompromised patients who cannot rely on their own immune system to finish clearing the infection.

Case reports offer a more nuanced real-world view. In a neonatal case involving a baby with congenital kidney and intestinal abnormalities, the clinical team initially started liposomal amphotericin B but switched to fluconazole after receiving susceptibility results. Despite systemic therapy, the infection persisted as a Candida pyelonephritis until a recto-vesical fistula was surgically repaired, after which the child recovered completely on a three-month course of fluconazole.¹⁸ The case underscores that antifungal drugs alone may not clear the infection if an underlying anatomical problem feeds the cycle.

Given the variable susceptibility patterns discussed earlier, empiric treatment with an echinocandin seems reasonable for suspected C. kefyr candidemia, with adjustment once susceptibility data are available. The growing reports of azole resistance argue against assuming fluconazole will work without testing.

Infections in Newborns

Neonates deserve special mention because their immature immune systems make them inherently vulnerable to opportunistic fungi, and C. kefyr has caused documented invasive disease in this population. The neonatal case referenced above is instructive: the baby developed C. kefyr candiduria after antibiotic treatment for a bacterial infection, a common sequence where broad-spectrum antibiotics disrupt normal flora and allow yeast overgrowth.¹⁸ Structural abnormalities like vesicoureteral reflux compounded the problem by allowing infected urine to repeatedly wash the kidneys.

What stood out in that report was the limited availability of resistance data for C. kefyr at the time, which made choosing the right drug harder. Antibiotic resistance profiles that hospitals maintain for common bacteria and common Candida species simply did not include C. kefyr. As infections accumulate, that gap is slowly closing, but pediatric infectious disease specialists managing these cases often still find themselves working with incomplete information.

The Probiotic and Industrial Side

C. kefyr’s dual life as both a potential pathogen and a useful microbe is one of the more unusual aspects of this organism. Under its formal name Kluyveromyces marxianus, it is valued in biotechnology for its ability to grow rapidly on a wide range of substrates and produce useful compounds like 2-phenylethanol, a rose-scented alcohol used in fragrances and flavoring, as well as ethanol. Certain strains have even been evaluated as probiotics, with results suggesting probiotic properties comparable to an established commercial strain.¹⁹

The probiotic angle has an immunological twist. In an animal study, mice fed C. kefyr showed shifts in their gut bacterial communities, with an increase in Lactobacillales and a decrease in Bacteroides, and these changes were associated with reduced inflammation in the central nervous system.²⁰ That is a provocative finding, suggesting the same yeast that causes invasive disease in vulnerable patients might benefit healthy ones by modulating gut flora and dampening inflammatory responses.

This paradox is not unique to C. kefyr. Many microorganisms that are benign or even beneficial in healthy hosts become pathogens when the immune system falters. But the contrast is especially stark here because C. kefyr straddles the food industry and the hospital ward more visibly than most opportunistic fungi. A practical implication is that the growing popularity of probiotic yeast products and artisanal fermented foods means more people are regularly ingesting strains closely related to those causing clinical infections. For the vast majority of people this is perfectly safe, but for immunocompromised individuals, consuming live yeast products without medical guidance is not a trivial decision.

Why Dairy and Hospital Strains May Not Be So Different

A natural question is whether the strains causing infections are genetically distinct from those found in food. The evidence is still limited, but what exists is unsettling. The large comparative study of clinical and environmental C. kefyr isolates found that biofilm formation and protease production were common across both groups, suggesting that food-associated strains are not inherently less virulent.⁸ The antifungal susceptibility study that included dairy product isolates found elevated fluconazole resistance even in strains from food, not just from hospital patients.¹³

The blurring of lines between environmental and clinical strains has implications for surveillance. If resistance traits are already circulating in non-clinical C. kefyr populations, then the hospital is not the only place where resistant strains originate. Agricultural use of antifungals, cross-contamination during food production, and the human gut acting as a mixing vessel for food-derived and commensal strains could all contribute to the resistance pool. This is a familiar story in antibacterial resistance, and mycologists are starting to recognize that the same dynamics apply to fungi.

1
Diagnostic Microbiology and Infectious Disease. Candida kefyr as an emerging cause of invasive fungal infection in transplant patients: Case report and literature review
2
PubMed. Growth characteristics of Candida kefyr and two strains of Lactococcus lactis subsp. lactis isolated from Zimbabwean naturally fermented milk
3
PubMed. Characterization, enzymatic activity and biofilm formation of Candida species isolated from goat milk
4
PubMed Central. Epidemiology of Candida kefyr in patients with hematologic malignancies
5
PubMed. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients
6
PubMed Central. The risk and clinical outcome of candidemia depending on underlying malignancy
7
PubMed Central. Prevalence and species distribution of Candida bloodstream infection in children and adults in two teaching university hospitals in Egypt: first report of Candida kefyr
8
PubMed Central. Comparative analysis of enzymatic profiles and biofilm formation in clinical and environmental Candida kefyr isolates
9
PubMed. Phospholipase and protease activities in clinical Candida isolates with reference to the sources of strains
10
Journal of Pure and Applied Microbiology. Pathogenicity Testing Of Clinical Candida Isolates By Assesing Biofilm Formation And Their Adhesion To Urinary Catheter Material
11
PubMed. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections
12
PubMed Central. Colonization of the bovine uterus by Candida kefyr
13
PubMed Central. Antifungal Susceptibility Profile of Candida kefyr Isolated from Clinical Samples and Dairy Products
14
Medical Mycology Case Reports. Two missense mutations, E123Q and K151E, identified in the ERG11 allele of an azole-resistant isolate of Candida kefyr recovered from a stem cell transplant patient for acute myeloid leukemia
15
PLOS ONE. Candida kefyr in Kuwait: Prevalence, antifungal drug susceptibility and genotypic heterogeneity
16
PubMed Central. New chromogenic agar medium for the identification of Candida spp.
17
PubMed. Antifungal therapies in murine infections by Candida kefyr
18
PubMed Central. Candidemia caused by Candida kefyr in a neonate: case report
19
PubMed Central. New generation probiotics: combining probiotic and biotechnological potential of Kluyveromyces marxianus
20
PubMed Central. Dietary Yeasts Reduce Inflammation in Central Nerve System via Microflora